Redhill Biopharm Stock Price, News & Analysis

RedHill Biopharma (RDHL) is accelerating its COVID-19 clinical programs for opaganib and RHB-107, showcasing their efficacy against the Omicron variant. A Phase 2/3 analysis revealed a 62% mortality reduction in moderately severe patients treated with opaganib. The company reported Q3 2021 net revenues of $21.6 million, with a gross margin increase to 57%. New strategic investments and a $15.5 million public offering bolster its financial position, while Talicia and Movantik continue to see prescription growth, with Talicia's revenue up 117% compared to Q3 2020.

RedHill Biopharma (Nasdaq: RDHL) will announce its Q3 2021 financial results and operational highlights on November 30, 2021. A webcast is scheduled for 8:30 a.m. EST, where key highlights will be presented. The webcast will be available for replay for 30 days. RedHill focuses on gastrointestinal and infectious diseases, promoting drugs like Movantik, Talicia, and Aemcolo. Ongoing clinical developments include RHB-204 for NTM disease and opaganib targeting COVID-19.

On November 23, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) announced the closing of an underwritten public offering of approximately 4.7 million American Depositary Shares (ADSs), raising about $15.5 million in gross proceeds. Each ADS represents ten ordinary shares and was offered by RedHill, which has granted a 30-day option to purchase approximately 0.7 million additional ADSs. The funds will support commercialization activities, clinical development programs, and general corporate purposes.

RedHill Biopharma Ltd. (Nasdaq: RDHL) has priced an underwritten public offering of 4.7 million American Depositary Shares (ADSs) for gross proceeds of $15.5 million. The offering is set to close around November 23, 2021, pending customary conditions. Each ADS represents ten ordinary shares, and the underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase up to an additional 0.7 million ADSs. Funds will support commercialization activities, clinical development, acquisitions, and general corporate purposes.

RedHill Biopharma Ltd. (Nasdaq: RDHL) announced an underwritten public offering of American Depositary Shares (ADSs), with each ADS representing ten ordinary shares. The offering includes a 30-day option for the underwriter to purchase up to 15% additional ADSs. Proceeds will fund commercialization, clinical development, acquisitions, and general corporate purposes. The offering is conducted under a shelf registration statement effective since August 8, 2019, and will not constitute an offer to sell or solicit any offer to buy securities.

RedHill Biopharma has completed the last patient enrollment in Part A of its Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19. This study is being conducted in the U.S. and South Africa, with top-line results expected in Q1 2022. RHB-107 is a novel antiviral designed to be effective against emerging viral variants. In parallel, data for another candidate, opaganib, has been submitted for regulatory reviews. RedHill focuses on gastrointestinal and infectious diseases, promoting treatments like Movantik and Talicia.

RedHill Biopharma (RDHL) has completed enrollment for Part A of its Phase 2/3 study of RHB-107 (upamostat), a once-daily oral treatment for symptomatic COVID-19 patients not requiring hospitalization. The study, conducted in the U.S. and South Africa, aims to evaluate safety, tolerability, and dose selection. Top-line results are expected in Q1 2022. RHB-107 targets human cell factors and aims to be effective against emerging variants. Concurrently, data packages for another COVID-19 drug, opaganib, have been submitted for regulatory review.

RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that Chief Business Officer Guy Goldberg will present at two upcoming virtual conferences: the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, and the German Equity Forum from November 22-24, 2021. The presentations will cover the company's biopharmaceutical focus on gastrointestinal and infectious diseases, including ongoing clinical trials for various therapies. Webcasts of both presentations will be available for 30 days post-event. More details can be found on RedHill's investor relations page.

RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered a strategic agreement with South Korea's Kukbo Co. Ltd. for a $10 million private placement, sold in two tranches. The first tranche of $5 million has been completed, issuing 827,586 American Depositary Shares (ADSs) at $6.04 each, a 20% premium. Kukbo will have a six-month option for licensing RedHill's late-stage clinical assets in select Asian territories. This investment aims to support the advancement of RedHill's COVID-19 therapeutic, opaganib, among others.